A Case Report on Effect of Asenapine Sublingual Tablets on Intractable Nausea in a Patient of Terminal Malignant Lymphoma with Diabetes Who Cannot Take Oral Medicine-Reference-Cited by-同舟云学术

A Case Report on Effect of Asenapine Sublingual Tablets on Intractable Nausea in a Patient of Terminal Malignant Lymphoma with Diabetes Who Cannot Take Oral Medicine

Published:2021 Issue:2 Volume:16 Page:133-138
ISSN:1880-5302
Container-title:Palliative Care Research
language:en
Short-container-title:Palliat Care Res

Author:

Watanabe Hiroyuki¹,Nakamura Kazuyuki¹,Ishikawa Ayumi¹,Lee Jinwoo²,Adachi Yasunori²,Nabeshima Toshitaka³⁴,Sugiura Yoji¹

Affiliation:

1. Department of Pharmacy, Anjo Kosei Hospital

2. Department of Palliative Medicine, Anjo Kosei Hospital

3. Japanese Drug Organization of Appropriate Use and Research

4. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences

Publisher

Japanese Society for Palliative Medicine

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jspm/16/2/16_133/_pdf

Reference17 articles.

1. 2) Mannix KA. Palliation of nausea and vomiting. In Doyle D, Hanks G, Cherny NI, et al. Oxford Textbook of Palliative Medicine, 3rd ed. Oxford University Press, New York, 2004; 459-468.

2. 4) Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the treatment of advanced cancer-related chronic nausea and/or vomiting: a randomized pilot trial. JAMA Oncol 2020; 6: 895-9.

3. 5) Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375: 134-42.

4. 6) Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 242-9.

5. 7) Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002; 23: 526-32.